We are proud to announce that IMCD Group has been appointed as a new distribution partner for sustainable microbial concentrates and additives across EMEA, further expanding the reach of our products into new territories worldwide.
IMCD Group is a leading distributor of speciality chemicals and ingredients, and this ideally suited partnership will see IMCD specifically showcase our Evogen and Evozyme biological products to the Home Care and I&I Cleaning markets across EMEA. They’ll also focus on strengthening our sales channels across the EU and overcoming the significant logistical challenges posed by Brexit.
Our Evogen fully formulated concentrates, which have been developed to ensure highly-efficacious long-term performance, are used for hard surface cleaning, soft surface cleaning and exterior cleaning and odour control, while the concentrated probiotic Evozyme additives can be used in a wide range of Home Care and I&I applications to produce high performing cleaning, odour control and FOG prevention products. Both solutions have been designed using application-specific Bacillus strains and reduce the need for harsh chemicals.
Conrad Mielcuszny, CEO of Genesis Biosciences, stated in response to this collaboration, “The partnership with IMCD is a very exciting step for Genesis and opens doors on a global level post-COVID and post-Brexit. The collaboration follows our recent commitment to establish new manufacturing partners across mainland Europe and will allow us to expand our audience and provide high level technical and commercial support to customers across EMEA.
“Our Evogen and Evozyme technologies are the result of years of scientific research and development to create more effective and ecological cleaning solutions while protecting the environment and we’re looking forward to introducing these solutions to new prospective clients.”
Speaking on our new partnership, Paul Hanbury, Director of Home Care and I&I at IMCD Group said, “We are seeing a growing demand for sustainable microbial ingredients across the entire Home Care and I&I sector. Our customers are looking for solutions that can deliver high levels of performance across all applications, without the need for harsh chemicals.
“The addition of a world-leading developer like Genesis, and its comprehensive range of microbial concentrates and additives, will enable us to deliver an unprecedented new level of sustainable material choice to our global network of customers and we are looking forward to a long and fruitful relationship.”
About IMCD Group
IMCD employs over 4,300 professionals and operates in over 50 countries across six continents, operating within a multitude of sectors include home care, industrial and institutional, health and beauty, food and nutrition, pharmaceuticals and more. They utilise their extensive local networks, market intelligence and technical expertise to help their principal partners to market, sell and distribute their products.
Like us, sustainability is at the forefront of IMCD’s operations and embedded in their business model. Our microbial and antimicrobial eco-benign® technology is used in all our products and is why, along with our efforts in reducing our environmental impact, we were named Green Business of the Year 2019. Our passion for driving positive environmental change through our products and our actions is also behind our achievement in offsetting 100% of our carbon emissions in 2021.
Our closely aligned values and shared goals in bringing sustainable microbial products to new markets is what makes this new distribution partnership so special.
The Genesis Biosciences and IMCD team celebrating new distribution partnership
Explore more related news
- Genesis Biosciences wins Prestige South East USA 2022 Award
- How we offset 100% of our carbon emissions in 2021
- Genesis Biosciences is now an approved supplier with the UK Government’s Crown Commercial Service
For more information on our products and initiatives, visit our About page.
If you’d like news from us delivered straight to your inbox, sign up to our regular newsletter.